Health Care · Laboratory Analytical Instruments

EYPT EyePoint, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1314102142 filings
Russell 2000

EYPT at a glance

EyePoint, Inc. (EYPT, SEC CIK 1314102) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 19, 2026 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), EyePoint, Inc. (EYPT) reported revenue of $31.4 million (down 27.5% from FY2024) and a net loss of $232.0 million. Diluted EPS was -$3.17.
  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding EyePoint, Inc. (EYPT) shares worth $94.2 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Zaderej Karen L. on August 18, 2026 of 10,600 shares at $4.93 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$31.4M
−27.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
29 funds
$94.2M · +2 vs prior quarter
Latest 8-K
Nov 19, 2026
Item 8.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Clinical-stage biopharma developing sustained intraocular drug delivery therapeutics for serious retinal diseases leveraging proprietary bioerodible Durasert E™ technology
  • New emphasized product: DURAVYU™, a novel multi-mechanism VEGF receptor, PDGF, and IL-6/JAK1 inhibitor in Phase 3 trials for wet AMD and DME, first patient dosed in DME Phase 3 in Feb 2026
  • Strategic shift: Transition from early to pivotal late-stage global Phase 3 trials with enrollment completion in two wet AMD studies (LUGANO, LUCIA) and initiation of two DME studies (COMO, CAPRI)
  • Quantitative metric: Over 900 patients enrolled across two Phase 3 wet AMD trials, additional ~480 patients planned for Phase 3 DME trials; Phase 2 VERONA trial showed +10.3 letters BCVA improvement in subgroup vs +3.0 aflibercept
  • Noteworthy fact: DURAVYU's intracellular multi-MOA acting on VEGF receptors plus anti-inflammatory IL-6 signaling constitutes a new treatment paradigm with potential 6-month sustained delivery reducing treatment burden by over 85%

Risk Factors

  • DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026
  • Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027
  • Manufacturing risk: inability to scale DURAVYU production could delay Phase 3 trials and commercialization
  • Competitive risk: approval and market acceptance of DURAVYU may be impacted by alternative wet AMD treatments and generics
  • Liquidity risk: $306.1M cash runway likely sufficient only through Q4 2027, requiring uncertain future capital raises that may dilute shareholders

Management Discussion & Analysis

  • Revenue $31.4M down 28% YoY from $43.3M; product sales fell 50% to $1.6M, license/collab revenues down 57% to $16.7M, royalty income up 708% to $13.0M
  • Operating expenses $274.8M up 45% YoY from $189.1M; R&D $221.0M up 66%, G&A $51.6M down 1%; operating loss $243.4M vs $145.9M, loss margin ~776% vs 337% (loss/net loss ÷ revenue)
  • Best segment: Royalty income $13.0M (+708%); Worst: License/collab revenue down $21.8M to $16.7M
  • Financing: Raised $172.5M via public offering + $11.6M ATM sales; cash and securities $306.1M at year-end; Operating cash outflow $240.1M; no buybacks or dividends disclosed
  • Outlook: Phase 3 DURAVYU trials enrollment complete, data expected mid-2026; first DME patient dosed Feb 2026; settled DOJ investigation in principle with ~$4.7M payment; cash runway into Q4 2027

AI summary of the EYPT 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue down 22% YoY, $0.7M versus $0.9M
  • Net loss $95.6M versus $59.7M; R&D $81.7M, up 71% YoY
  • DURAVYU R&D $55.3M versus $29.6M, strongest spending increase
  • Nine-month operating cash outflow $229.7M versus $175.1M; capital expenditures $3.4M
  • Cash, equivalents and investments $118.2M; runway into late Q3 2027 after $10.1M ATM proceeds

Risk Factors

  • Going-concern risk: September 30 cash, equivalents and short-term investments insufficient for 12 months without additional funding
  • Strategic prioritization risk: October 19 plan ends pivotal wet AMD trials early and reduces workforce approximately 53%
  • Operational risk: workforce reduction may cause loss of expertise and delays to DURAVYU DME development
  • Nasdaq compliance risk: $0.4041 closing price on November 10 versus $1.00 minimum bid requirement
  • Market risk: shares declined significantly after LUGANO and LUCIA trial results announced in August and October 2026

AI summary of the EYPT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 19, 2026Full analysis →

Item 8.01: Other Events

  • Securities class action filed November 17, 2026 against EyePoint and executive officers
  • Putative class covers investors acquiring securities from May 27, 2025 through August 14, 2026
Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • EyePoint announced financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed financial results and accompanying company updates

Item EX-99.1: Item EX-99.1

  • DME becomes EyePoint’s sole late-stage focus after wet AMD Phase 3 failures on primary BCVA non-inferiority endpoints
  • COMO and CAPRI fully enrolled with over 550 patients, topline data expected early Q4 2027
Filed Oct 19, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Preliminary cash, cash equivalents and short-term investments reported as of September 30, 2026
  • Liquidity figures remain unaudited and may change after quarter-end financial statement completion

Item 2.05: Costs Associated with Exit or Disposal Activities

  • Wet AMD Phase 3 trials to end early after LUCIA topline review, signaling reduced development prospects for DURAVYU in wet AMD
  • Resources redirected to late-stage DME trials, COMO and CAPRI

Item 8.01: Other Events

  • EyePoint announced a “Prioritization” initiative, signaling a potential shift in strategic or capital-allocation focus
  • Investor impact depends on Exhibit 99.1, which contains the underlying details and expected business implications

Item EX-99.1: Item EX-99.1

  • LUCIA Phase 3 wet AMD trial missed non-inferiority primary endpoint, ending EyePoint’s lead indication path
  • Wet AMD pivotal trials to stop early, reducing development value but limiting further trial spending

AI summaries of EYPT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for EYPT

Don't miss the next EYPT filing

  • Alerts as it files. A push when EYPT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut EYPT, by share count.
  • Ask anything. An AI agent that reads every EYPT filing and answers with sources.

EYPT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Elston GeorgeGAug 20, 2026-
Elston GeorgeJAug 20, 2026-
Elston GeorgeJAug 20, 2026-
Elston GeorgeGAug 20, 2026-
Zaderej Karen L.BuyAug 18, 2026$4.93
Duker Jay S.MJul 10, 2026-
Duker Jay S.FJul 10, 2026$14.72
Duker Jay S.MJul 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$43.3M$31.4M
Operating Income--$145.9M-$243.4M
Net Income-$70.8M-$130.9M-$232.0M
Op. Margin--337.1%-776.0%
Net Margin--302.4%-739.4%
Balance Sheet
Total Assets$355.2M$418.5M$364.0M
Equity-$336.5M$306.1M
ROE--38.9%-75.8%
Per Share
EPS$-1.82$-2.32$-3.17
Cash Flow
Operating CF--$126.2M-$240.1M
CapEx$3.5M$4.1M$3.3M

Source: XBRL data in EyePoint, Inc. (EYPT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate EYPT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
EYPT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$94.2M
Q2 202627$388.2M
Q1 202629$336.5M
Q4 202525$335.7M
Q3 202523$320.9M
Q2 202524$214.6M
Q1 202520$96.3M
Q4 202416$104.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 193 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

EYPT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 19, 2026Analysis-
8-KNov 12, 2026Analysis-
10-QNov 12, 2026Analysis
8-KOct 19, 2026Analysis-
8-KOct 19, 2026Analysis-
8-KSep 10, 2026Analysis-
SC 13GSep 8, 2026-
4Aug 24, 2026--
4Aug 18, 2026--
8-KAug 17, 2026Analysis-
SC 13GAug 12, 2026-
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
SC 13GJul 31, 2026-
8-KJul 30, 2026Analysis-
8-KJul 17, 2026Analysis-
4Jul 14, 2026--
4Jul 2, 2026--
8-KJun 22, 2026Analysis-
SC 13GJun 3, 2026-
4May 27, 2026-
8-KMay 14, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 6, 2026Analysis
4Apr 20, 2026--

Related Health Care companies

All Health Care →

EYPT SEC filings: frequently asked questions

Which institutions hold EYPT stock?

As of September 30, 2026, the largest EyePoint, Inc. (EYPT) holders among the 13F filers tracked by SignalX were BlackRock ($26.1 million), Vanguard Capital Management LLC ($12.0 million), State Street Corp ($9.7 million), Millennium Management ($6.8 million), Citadel Advisors LLC ($6.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was EYPT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), EyePoint, Inc. (EYPT) reported revenue of $31.4 million (down 27.5% from FY2024) and a net loss of $232.0 million. Diluted EPS was -$3.17. The figures come from the XBRL data in the 10-K.

What are the main risks in EYPT's latest 10-K?

In the 10-K filed March 5, 2026, EyePoint, Inc. (EYPT) flagged: DOJ investigation under False Claims Act and Anti-Kickback Statute with $4.7M proposed settlement plus corporate integrity agreement, finalization expected H1 2026. Clinical trial delay risk: DURAVYU Phase 3 topline data expected in 2026, cash runway extends only into Q4 2027. (AI summary of the Risk Factors section.)

What did EYPT report in its latest 8-K?

EyePoint, Inc. (EYPT) filed an 8-K on November 19, 2026 reporting Item 8.01 (Other Events). Securities class action filed November 17, 2026 against EyePoint and executive officers.

What are the latest EYPT SEC filings?

EyePoint, Inc. (EYPT) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 19, 2026 and a Form 4 insider filing on August 24, 2026.

What is EYPT's SEC CIK number?

EyePoint, Inc. (EYPT)'s SEC Central Index Key (CIK) is 1314102. EDGAR lists every EYPT filing under that number.

Ask anything about EYPT

The research agent reads EYPT's filings, financials, insider trades and 13F holders, then answers with sources.